Transdermal Drug Delivery System Market in Japan - Industry Outlook and Forecast 2020-2026

April 2020 | 106 pages | ID: T6466DF7C02FEN
Market Monitor Global

Abstracts

Transdermal Drug Delivery System is a medicated adhesive patch that is placed on the skin to deliver a specific dose of medication through the skin and into the bloodstream. Often, this promotes healing to an injured area of the body. An advantage of a transdermal drug delivery route over other types of medication delivery such as oral, topical, intravenous, intramuscular, etc. is that the patch provides a controlled release of the medication into the patient, usually through either a porous membrane covering a reservoir of medication or through body heat melting thin layers of medication embedded in the adhesive.
This report contains market size and forecasts of Transdermal Drug Delivery System in Japan, including the following market information:
Japan Transdermal Drug Delivery System Market Revenue, 2015-2020, 2021-2026, ($ millions)
Top Five Competitors in Japan Transdermal Drug Delivery System Market 2019 (%)
The global Transdermal Drug Delivery System market was valued at 11960 million in 2019 and is projected to reach US$ 19320 million by 2026, at a CAGR of 12.7% during the forecast period. While the Transdermal Drug Delivery System market size in Japan was US$ XX million in 2019, and it is expected to reach US$ XX million by the end of 2026, with a CAGR of XX% during 2020-2026.
COVID-19 pandemic has big impact on Transdermal Drug Delivery System businesses, with lots of challenges and uncertainty faced by many players of Transdermal Drug Delivery System in Japan. This report also analyses and evaluates the COVID-19 impact on Transdermal Drug Delivery System market size in 2020 and the next few years in Japan

Total Market by Segment:

Japan Transdermal Drug Delivery System Market, By Type, 2015-2020, 2021-2026 ($ millions)
Japan Transdermal Drug Delivery System Market Segment Percentages, By Type, 2019 (%)

• Fentanyl
• Nitroglycerin
• Estradiol
• Nicotine
• Other

Japan Transdermal Drug Delivery System Market, By Application, 2015-2020, 2021-2026 ($ millions)
Japan Transdermal Drug Delivery System Market Segment Percentages, By Application, 2019 (%)

• OTC
• Rx

Competitor Analysis

The report also provides analysis of leading market participants including:

Total Transdermal Drug Delivery System Market Competitors Revenues in Japan, by Players 2015-2020 (Estimated), ($ millions)
Total Transdermal Drug Delivery System Market Competitors Revenues Share in Japan, by Players 2019 (%)
Further, the report presents profiles of competitors in the market, including the following:

• Hisamitsu
• Mylan
• GSK
• Novartis
• Teve (Actavis)
• Johnson & Johnson
• Lohmann
• Teikoku Seiyaku
• Bayer
• Lingrui
• Sanofi
• Qizheng
• Endo
• Huarun 999
• Haw Par
• Nichiban
• Mentholatum

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Transdermal Drug Delivery System Market Definition
1.2 Market Segments
  1.2.1 Segment by Type
  1.2.2 Segment by Application
1.3 COVID-19 Impact: Japan Transdermal Drug Delivery System Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 JAPAN TRANSDERMAL DRUG DELIVERY SYSTEM OVERALL MARKET SIZE

2.1 Japan Transdermal Drug Delivery System Market Size: 2020 VS 2026
2.2 Japan Transdermal Drug Delivery System Revenue, Prospects & Forecasts: 2015-2026

3 COMPANY LANDSCAPE

3.1 Top Transdermal Drug Delivery System Players in Japan (including Foreign and Local Companies)
3.2 Top Japan Transdermal Drug Delivery System Companies Ranked by Revenue
3.3 Japan Transdermal Drug Delivery System Revenue by Companies (including Foreign and Local Companies)
3.4 Top 3 and Top 5 Transdermal Drug Delivery System Companies in Japan, by Revenue in 2019
3.5 Japan Manufacturers Transdermal Drug Delivery System Product Type
3.6 Tier 1, Tier 2 and Tier 3 Transdermal Drug Delivery System Players in Japan
  3.6.1 List of Japan Tier 1 Transdermal Drug Delivery System Companies
  3.6.2 List of Japan Tier 2 and Tier 3 Transdermal Drug Delivery System Companies

4 SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 By Type - Japan Transdermal Drug Delivery System Market Size Markets, 2020 & 2026
  4.1.2 Fentanyl
  4.1.3 Nitroglycerin
  4.1.4 Estradiol
  4.1.5 Nicotine
  4.1.6 Other
4.2 By Type - Japan Transdermal Drug Delivery System Revenue & Forecasts
  4.2.1 By Type - Japan Transdermal Drug Delivery System Revenue, 2015-2020
  4.2.2 By Type - Japan Transdermal Drug Delivery System Revenue, 2021-2026
  4.2.3 By Type - Japan Transdermal Drug Delivery System Revenue Market Share, 2015-2026

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Japan Transdermal Drug Delivery System Market Size, 2020 & 2026
  5.1.2 OTC
  5.1.3 Rx
5.2 By Application - Japan Transdermal Drug Delivery System Revenue & Forecasts
  5.2.1 By Application - Japan Transdermal Drug Delivery System Revenue, 2015-2020
  5.2.2 By Application - Japan Transdermal Drug Delivery System Revenue, 2021-2026
  5.2.3 By Application - Japan Transdermal Drug Delivery System Revenue Market Share, 2015-2026

6 PLAYERS PROFILES

6.1 Hisamitsu
  6.1.1 Hisamitsu Corporate Summary
  6.1.2 Hisamitsu Business Overview
  6.1.3 Hisamitsu Transdermal Drug Delivery System Major Product Offerings
  6.1.4 Hisamitsu Revenue in Japan (2015-2020)
  6.1.5 Hisamitsu Key News
6.2 Mylan
  6.2.1 Mylan Corporate Summary
  6.2.2 Mylan Business Overview
  6.2.3 Mylan Transdermal Drug Delivery System Major Product Offerings
  6.2.4 Mylan Revenue in Japan (2015-2020)
  6.2.5 Mylan Key News
6.3 GSK
  6.3.1 GSK Corporate Summary
  6.3.2 GSK Business Overview
  6.3.3 GSK Transdermal Drug Delivery System Major Product Offerings
  6.3.4 GSK Revenue in Japan (2015-2020)
  6.3.5 GSK Key News
6.4 Novartis
  6.4.1 Novartis Corporate Summary
  6.4.2 Novartis Business Overview
  6.4.3 Novartis Transdermal Drug Delivery System Major Product Offerings
  6.4.4 Novartis Revenue in Japan (2015-2020)
  6.4.5 Novartis Key News
6.5 Teve (Actavis)
  6.5.1 Teve (Actavis) Corporate Summary
  6.5.2 Teve (Actavis) Business Overview
  6.5.3 Teve (Actavis) Transdermal Drug Delivery System Major Product Offerings
  6.5.4 Teve (Actavis) Revenue in Japan (2015-2020)
  6.5.5 Teve (Actavis) Key News
6.6 Johnson & Johnson
  6.6.1 Johnson & Johnson Corporate Summary
  6.6.2 Johnson & Johnson Business Overview
  6.6.3 Johnson & Johnson Transdermal Drug Delivery System Major Product Offerings
  6.6.4 Johnson & Johnson Revenue in Japan (2015-2020)
  6.6.5 Johnson & Johnson Key News
6.7 Lohmann
  6.6.1 Lohmann Corporate Summary
  6.6.2 Lohmann Business Overview
  6.6.3 Lohmann Transdermal Drug Delivery System Major Product Offerings
  6.4.4 Lohmann Revenue in Japan (2015-2020)
  6.7.5 Lohmann Key News
6.8 Teikoku Seiyaku
  6.8.1 Teikoku Seiyaku Corporate Summary
  6.8.2 Teikoku Seiyaku Business Overview
  6.8.3 Teikoku Seiyaku Transdermal Drug Delivery System Major Product Offerings
  6.8.4 Teikoku Seiyaku Revenue in Japan (2015-2020)
  6.8.5 Teikoku Seiyaku Key News
6.9 Bayer
  6.9.1 Bayer Corporate Summary
  6.9.2 Bayer Business Overview
  6.9.3 Bayer Transdermal Drug Delivery System Major Product Offerings
  6.9.4 Bayer Revenue in Japan (2015-2020)
  6.9.5 Bayer Key News
6.10 Lingrui
  6.10.1 Lingrui Corporate Summary
  6.10.2 Lingrui Business Overview
  6.10.3 Lingrui Transdermal Drug Delivery System Major Product Offerings
  6.10.4 Lingrui Revenue in Japan (2015-2020)
  6.10.5 Lingrui Key News
6.11 Sanofi
  6.11.1 Sanofi Corporate Summary
  6.11.2 Sanofi Transdermal Drug Delivery System Business Overview
  6.11.3 Sanofi Transdermal Drug Delivery System Major Product Offerings
  6.11.4 Sanofi Revenue in Japan (2015-2020)
  6.11.5 Sanofi Key News
6.12 Qizheng
  6.12.1 Qizheng Corporate Summary
  6.12.2 Qizheng Transdermal Drug Delivery System Business Overview
  6.12.3 Qizheng Transdermal Drug Delivery System Major Product Offerings
  6.12.4 Qizheng Revenue in Japan (2015-2020)
  6.12.5 Qizheng Key News
6.13 Endo
  6.13.1 Endo Corporate Summary
  6.13.2 Endo Transdermal Drug Delivery System Business Overview
  6.13.3 Endo Transdermal Drug Delivery System Major Product Offerings
  6.13.4 Endo Revenue in Japan (2015-2020)
  6.13.5 Endo Key News
6.14 Huarun
  6.14.1 Huarun 999 Corporate Summary
  6.14.2 Huarun 999 Transdermal Drug Delivery System Business Overview
  6.14.3 Huarun 999 Transdermal Drug Delivery System Major Product Offerings
  6.14.4 Huarun 999 Revenue in Japan (2015-2020)
  6.14.5 Huarun 999 Key News
6.15 Haw Par
  6.15.1 Haw Par Corporate Summary
  6.15.2 Haw Par Transdermal Drug Delivery System Business Overview
  6.15.3 Haw Par Transdermal Drug Delivery System Major Product Offerings
  6.15.4 Haw Par Revenue in Japan (2015-2020)
  6.15.5 Haw Par Key News
6.16 Nichiban
  6.16.1 Nichiban Corporate Summary
  6.16.2 Nichiban Transdermal Drug Delivery System Business Overview
  6.16.3 Nichiban Transdermal Drug Delivery System Major Product Offerings
  6.16.4 Nichiban Revenue in Japan (2015-2020)
  6.16.5 Nichiban Key News
6.17 Mentholatum
  6.17.1 Mentholatum Corporate Summary
  6.17.2 Mentholatum Transdermal Drug Delivery System Business Overview
  6.17.3 Mentholatum Transdermal Drug Delivery System Major Product Offerings
  6.17.4 Mentholatum Revenue in Japan (2015-2020)
  6.17.5 Mentholatum Key News
6.18 Laboratoires Genevrier
  6.18.1 Laboratoires Genevrier Corporate Summary
  6.18.2 Laboratoires Genevrier Transdermal Drug Delivery System Business Overview
  6.18.3 Laboratoires Genevrier Transdermal Drug Delivery System Major Product Offerings
  6.18.4 Laboratoires Genevrier Revenue in Japan (2015-2020)
  6.18.5 Laboratoires Genevrier Key News

7 KEY MARKET TRENDS & INFLUENCES 2021-2026

7.1 PESTLE Analysis for Japan Transdermal Drug Delivery System Market
7.2 Market Opportunities & Trends
7.3 Market Drivers
7.4 Market Restraints

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Key Players of Transdermal Drug Delivery System in Japan
Table 2. Top Players in Japan, Ranking by Revenue (2019)
Table 3. Japan Transdermal Drug Delivery System Revenue by Companies, (US$, Mn), 2015-2020
Table 4. Japan Transdermal Drug Delivery System Revenue Share by Companies, 2015-2020
Table 5. Japan Transdermal Drug Delivery System Sales by Companies, (K Units), 2015-2020
Table 6. Japan Transdermal Drug Delivery System Sales Share by Companies, 2015-2020
Table 7. Key Manufacturers Transdermal Drug Delivery System Price (2015-2020) (US$/Unit)
Table 8. Japan Manufacturers Transdermal Drug Delivery System Product Type
Table 9. List of Japan Tier 1 Transdermal Drug Delivery System Companies, Revenue (US$, Mn) in 2019 and Market Share
Table 10. List of Japan Tier 2 and Tier 3 Transdermal Drug Delivery System Companies, Revenue (US$, Mn) in 2019 and Market Share
Table 11. By Type - Transdermal Drug Delivery System Revenue in Japan (US$, Mn), 2015-2020
Table 12. By Type - Transdermal Drug Delivery System Revenue in Japan (US$, Mn), 2021-2026
Table 13. By Type - Transdermal Drug Delivery System Sales in Japan (K Units), 2015-2020
Table 14. By Type - Transdermal Drug Delivery System Sales in Japan (K Units), 2021-2026
Table 15. By Application - Transdermal Drug Delivery System Revenue in Japan, (US$, Mn), 2015-2020
Table 16. By Application - Transdermal Drug Delivery System Revenue in Japan, (US$, Mn), 2021-2026
Table 17. By Application - Transdermal Drug Delivery System Sales in Japan, (K Units), 2015-2020
Table 18. By Application - Transdermal Drug Delivery System Sales in Japan, (K Units), 2021-2026
Table 19. Hisamitsu Corporate Summary
Table 20. Hisamitsu Transdermal Drug Delivery System Product Offerings
Table 21. Hisamitsu Transdermal Drug Delivery System Revenue (US$, Mn), (2015-2020)
Table 22. Mylan Corporate Summary
Table 23. Mylan Transdermal Drug Delivery System Product Offerings
Table 24. Mylan Transdermal Drug Delivery System Revenue (US$, Mn), (2015-2020)
Table 25. GSK Corporate Summary
Table 26. GSK Transdermal Drug Delivery System Product Offerings
Table 27. GSK Transdermal Drug Delivery System Revenue (US$, Mn), (2015-2020)
Table 28. Novartis Corporate Summary
Table 29. Novartis Transdermal Drug Delivery System Product Offerings
Table 30. Novartis Transdermal Drug Delivery System Revenue (US$, Mn), (2015-2020)
Table 31. Teve (Actavis) Corporate Summary
Table 32. Teve (Actavis) Transdermal Drug Delivery System Product Offerings
Table 33. Teve (Actavis) Transdermal Drug Delivery System Revenue (US$, Mn), (2015-2020)
Table 34. Johnson & Johnson Corporate Summary
Table 35. Johnson & Johnson Transdermal Drug Delivery System Product Offerings
Table 36. Johnson & Johnson Transdermal Drug Delivery System Revenue (US$, Mn), (2015-2020)
Table 37. Lohmann Corporate Summary
Table 38. Lohmann Transdermal Drug Delivery System Product Offerings
Table 39. Lohmann Transdermal Drug Delivery System Revenue (US$, Mn), (2015-2020)
Table 40. Teikoku Seiyaku Corporate Summary
Table 41. Teikoku Seiyaku Transdermal Drug Delivery System Product Offerings
Table 42. Teikoku Seiyaku Transdermal Drug Delivery System Revenue (US$, Mn), (2015-2020)
Table 43. Bayer Corporate Summary
Table 44. Bayer Transdermal Drug Delivery System Product Offerings
Table 45. Bayer Transdermal Drug Delivery System Revenue (US$, Mn), (2015-2020)
Table 46. Lingrui Corporate Summary
Table 47. Lingrui Transdermal Drug Delivery System Product Offerings
Table 48. Lingrui Transdermal Drug Delivery System Revenue (US$, Mn), (2015-2020)
Table 49. Sanofi Corporate Summary
Table 50. Sanofi Transdermal Drug Delivery System Product Offerings
Table 51. Sanofi Transdermal Drug Delivery System Revenue (US$, Mn), (2015-2020)
Table 52. Qizheng Corporate Summary
Table 53. Qizheng Transdermal Drug Delivery System Product Offerings
Table 54. Qizheng Transdermal Drug Delivery System Revenue (US$, Mn), (2015-2020)
Table 55. Endo Corporate Summary
Table 56. Endo Transdermal Drug Delivery System Product Offerings
Table 57. Endo Transdermal Drug Delivery System Revenue (US$, Mn), (2015-2020)
Table 58. Huarun 999 Corporate Summary
Table 59. Huarun 999 Transdermal Drug Delivery System Product Offerings
Table 60. Huarun 999 Transdermal Drug Delivery System Revenue (US$, Mn), (2015-2020)
Table 61. Haw Par Corporate Summary
Table 62. Haw Par Transdermal Drug Delivery System Product Offerings
Table 63. Haw Par Transdermal Drug Delivery System Revenue (US$, Mn), (2015-2020)
Table 64. Nichiban Corporate Summary
Table 65. Nichiban Transdermal Drug Delivery System Product Offerings
Table 66. Nichiban Transdermal Drug Delivery System Revenue (US$, Mn), (2015-2020)
Table 67. Mentholatum Corporate Summary
Table 68. Mentholatum Transdermal Drug Delivery System Product Offerings
Table 69. Mentholatum Transdermal Drug Delivery System Revenue (US$, Mn), (2015-2020)
Table 70. Laboratoires Genevrier Corporate Summary
Table 71. Laboratoires Genevrier Transdermal Drug Delivery System Product Offerings
Table 72. Laboratoires Genevrier Transdermal Drug Delivery System Revenue (US$, Mn), (2015-2020)

List Of Figures

LIST OF FIGURES

Figure 1. Transdermal Drug Delivery System Segment by Type
Figure 2. Transdermal Drug Delivery System Segment by Application
Figure 3. Japan Transdermal Drug Delivery System Market Overview: 2020
Figure 4. Key Caveats
Figure 5. Transdermal Drug Delivery System Market Size in Japan, (US$, Mn): 2020 VS 2026
Figure 6. Japan Transdermal Drug Delivery System Revenue, 2015-2026 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Transdermal Drug Delivery System Revenue in 2019
Figure 8. By Type - Japan Transdermal Drug Delivery System Incremental Growth, (US$, Mn), 2015-2026
Figure 9. By Type - Japan Transdermal Drug Delivery System Market Share, 2015-2026
Figure 10. By Application - Transdermal Drug Delivery System Revenue in Japan (US$, Mn), 2020 & 2026
Figure 11. By Application - Japan Transdermal Drug Delivery System Market Share, 2015-2026
Figure 12. PEST Analysis for Japan Transdermal Drug Delivery System Market in 2020
Figure 13. Transdermal Drug Delivery System Market Opportunities & Trends in Japan
Figure 14. Transdermal Drug Delivery System Market Drivers in Japan